Eight trials met the inclusion criteria (n=7,229 patients, range 66 to 2,287). Mean follow-up was 4.3 years (range one to five years). None of the trials concealed allocation or reported using any blinding. Seven trials reported reasons for withdrawals.
Overall there were 649 deaths (OR 0.98, 95% CI 0.83 to 1.15; Ι²=0), 322 out of 3,617 patients in the stent arms (8.9%), and 327 out of 3,612 patients in the medical therapy arms (9.1%). There was no statistically significant difference between the stent and medical therapy groups for nonfatal myocardial infarction, unplanned revascularization, or persistent angina, either overall or in the subgroup analyses conducted.
There was no evidence of publication bias.